Novavax's COVID-Influenza Combo and High-dose COVID Vaccine Show Strong Immune Response in Phase 2 Trial.

Novavax's COVID-Influenza Combination, stand-alone influenza, and high-dose COVID vaccine candidates have demonstrated robust immune responses in a Phase 2 trial. The trial evaluated the safety and effectiveness of different formulations of the vaccine candidates in adults aged 50 through 80. All three vaccine candidates contained Novavax's patented Matrix-M adjuvant and showed reassuring preliminary safety profiles and reactogenicity that was comparable to authorized influenza vaccine comparators. The CIC vaccine candidate achieved both immunoglobulin G (IgG) and neutralizing levels comparable to Novavax's prototype COVID vaccine (NVX-CoV2373).